Yasuhiro Kato

assistant professor

Nippon Medical School

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yasuhiro Kato is an assistant professor at Nippon Medical School in Japan. His research primarily focuses on the treatment of lung cancer, diabetes mellitus, and the characteristics of patients with COVID-19. His recent publications include studies on chemotherapy hydration techniques, resistance mechanisms in cancer therapies, and the efficacy of novel treatments for patients with specific genetic mutations.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Kei Morikawa

St. Marianna University School of Medicine

JAPAN

View details

Susumu Takeuchi

M.D., Ph.D., Assistant professor

Nippon Medical School

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yasuhiro Kato

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Effect of type 2 diabetes mellitus on systemic treatment for advanced non-small cell lung cancer

Phase II Study of Short Hydration without Diuretics for Cisplatin-Based Chemotherapy

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study

Opioid-induced nausea and vomiting: a dexamethasone multicentre prospective study

Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan

First-line Osimertinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer Patients with Poor Performance Status

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations

Collaborators (2)

Kei Morikawa

Susumu Takeuchi

Make your next move.